CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma
- 12 August 2023
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 37 (10) , 2050-2057
Abstract
T cell lymphomas (TCL) are heterogeneous, aggressive, and have few available targeted therapeutics. In this study, we determined that CD6, an established T cell marker, was expressed at high levels on almost all examined TCL patient specimens, suggesting that CD6 could be a new therapeutic target for this life-threatening blood cancer. We prepared a CD6-targeted antibody-drug conjugate (CD6-ADC) by conjugating monomethyl auristatin E (MMAE), an FDA-approved mitotic toxin, to a high-affinity anti-human CD6 monoclonal antibody (mAb). In contrast to both the unconjugated anti-CD6 mAb, and the non-binding control ADC, CD6-ADC potently and selectively killed TCL cells in vitro in both time- and concentration-dependent manners. It also prevented the development of tumors in vivo in a preclinical model of TCL. More importantly, systemic or local administration of the CD6-ADC or its humanized version, but not the controls, significantly shrank established tumors in the preclinical mouse model of TCL. These results suggest that CD6 is a novel therapeutic target in TCLs and provide a strong rationale for the further development of CD6-ADC as a promising therapy for patients with these potentially fatal lymphoid neoplasms.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA275639)
This publication has 23 references indexed in Scilit:
- The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in MiceCancer Cell, 2016
- Human treg cells are characterized by low/negative CD6 expressionCytometry Part A, 2014
- Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-cell LymphomasAmerican Journal of Surgical Pathology, 2014
- MYC expression and distribution in normal mature lymphoid cellsThe Journal of Pathology, 2013
- The CD6 Scavenger Receptor Is Differentially Expressed on a CD56dim Natural Killer Cell Subpopulation and Contributes to Natural Killer-Derived Cytokine and Chemokine SecretionJournal of Innate Immunity, 2010
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical OutcomesJournal of Clinical Oncology, 2008
- cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activityBlood, 2003
- High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndromeRheumatology, 2001
- CD30 defines a subset of activated human T cells that produce IFN-gamma and IL-5 and exhibit enhanced B cell helper activity.The Journal of Immunology, 1994
- A novel human T cell antigen preferentially expressed on mature T cells and shared by both well and poorly differentiated B cell leukemias and lymphomas.The Journal of Immunology, 1981